LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

Home・Akcijų sąrašas・AnaptysBio Inc

AnaptysBio Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

51.39 1.86

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

49.8

Max

51.39

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-102M -53M
Pardavimai	-83M 26M
Pelnas, tenkantis vienai akcijai	-1.843
Pelno marža	-206.934
Darbuotojai	104
EBITDA	-102M -34M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+47.41% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-430M 1.5B
Ankstesnė atidarymo kaina	49.53
Ankstesnė uždarymo kaina	51.39

Naujienos nuotaikos

By Acuity

93%

319 / 344 reitingas Healthcare

AnaptysBio Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-08 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026-06-08 15:41; UTC

Pagrindinės rinkos jėgos

American Battery Shares Jump on Energy Department Victory

2026-06-08 23:46; UTC

Rinkos pokalbiai

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026-06-08 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026-06-08 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Agrees to Buy m3ter

2026-06-08 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-08 19:22; UTC

Rinkos pokalbiai

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026-06-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026-06-08 18:17; UTC

Rinkos pokalbiai

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026-06-08 17:32; UTC

Rinkos pokalbiai

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-08 16:55; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026-06-08 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026-06-08 16:40; UTC

Rinkos pokalbiai

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026-06-08 16:31; UTC

Rinkos pokalbiai

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026-06-08 16:27; UTC

Rinkos pokalbiai

Mexican Inflation Seen Easing in May -- Market Talk

2026-06-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-08 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Orange Bought Stake From Lorca

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Acquires 100% Ownership of MasOrange

2026-06-08 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 15:58; UTC

Rinkos pokalbiai

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026-06-08 15:55; UTC

Rinkos pokalbiai

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026-06-08 15:41; UTC

Rinkos pokalbiai

Gold Falls Below 200-Day Moving Average -- Market Talk

Akcijų palyginimas

Kainos pokytis

AnaptysBio Inc Prognozė

Kainos tikslas

By TipRanks

47.41% į viršų

12 mėnesių prognozė

Vidutinis 75.71 USD 47.41%

Aukščiausias 93 USD

Žemiausias 66 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AnaptysBio Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių AnaptysBio Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

319 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.